Renaissance Technologies LLC Has $4.47 Million Position in Bioventus Inc. $BVS

Renaissance Technologies LLC lessened its holdings in shares of Bioventus Inc. (NASDAQ:BVS) by 20.4% during the 1st quarter, Holdings Channel.com reports. The fund owned 489,460 shares of the company’s stock after selling 125,640 shares during the period. Renaissance Technologies LLC’s holdings in Bioventus were worth $4,469,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Sei Investments Co. increased its stake in shares of Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after purchasing an additional 178,539 shares during the last quarter. Globeflex Capital L P lifted its stake in shares of Bioventus by 59.6% in the 1st quarter. Globeflex Capital L P now owns 123,052 shares of the company’s stock valued at $1,123,000 after purchasing an additional 45,936 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Bioventus by 14.1% in the first quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after purchasing an additional 107,930 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Bioventus by 11.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 79,913 shares of the company’s stock worth $730,000 after purchasing an additional 8,225 shares in the last quarter. Finally, Hillsdale Investment Management Inc. raised its holdings in Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after buying an additional 401,230 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BVS shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Craig Hallum reissued a “buy” rating and set a $18.00 price objective on shares of Bioventus in a report on Thursday. Barrington Research set a $18.00 price objective on Bioventus in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.25.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported second-quarter revenue of $153.2 million, up 4% year over year, while adjusted EPS rose to $0.22 from $0.21 and matched analyst expectations. Pain Treatments revenue increased 11.5%, led by strong Durolane volume growth. Bioventus Reports Second Quarter Financial Results
• Positive Sentiment: GAAP diluted EPS jumped to $0.47 from $0.11, and net income attributable to Bioventus rose to $33.4 million from $7.5 million. However, much of the GAAP improvement was related to the removal of a $24.6 million deferred-tax valuation allowance, rather than underlying operating growth. Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed
• Positive Sentiment: The board disclosed an unsolicited acquisition proposal and other expressions of interest and formed an independent committee, advised by Evercore and Latham & Watkins, to evaluate options including a sale. A transaction could provide a takeover premium and is likely supporting investor interest in BVS. $600M Durham company weighs sale as stock soars
• Positive Sentiment: Bioventus reaffirmed 2026 guidance for revenue of $600 million to $610 million, adjusted EPS of $0.75 to $0.79 and operating cash flow of $84 million to $89 million. It also made a $20 million term-loan prepayment, reducing debt and future interest costs. Bioventus outlines 2026 net leverage below 1.5x while board reviews strategic options
• Neutral Sentiment: The strategic review has no timetable and may end with no transaction, leaving BVS exposed to deal-related volatility. Surgical Solutions revenue fell 4.5% and Restorative Therapies revenue declined 2.4%, partly offsetting Pain Treatments growth.

Bioventus Stock Performance

NASDAQ:BVS opened at $13.98 on Friday. The firm has a market capitalization of $1.17 billion, a PE ratio of 18.16, a PEG ratio of 1.94 and a beta of 0.63. Bioventus Inc. has a 1 year low of $6.26 and a 1 year high of $15.89. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The firm’s fifty day simple moving average is $10.70 and its 200 day simple moving average is $9.66.

Bioventus (NASDAQ:BVS) last released its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 29.77%. The firm had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts anticipate that Bioventus Inc. will post 0.79 EPS for the current year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.